BioLineRx (BLRX) Tops Q3 EPS by 6c

BioLineRx (NASDAQ: BLRX) reported Q3 EPS of ($0.02), $0.06 better than the analyst estimate of ($0.08).

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
• Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings